| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2K | +27.3% | — |
| Cost of Revenue | $1K | +32.6% | — |
| Gross Profit | $1K | +23.8% | — |
| R&D Expense | $727K | -27.1% | -39.4% |
| SG&A Expense | $1.3M | +53.5% | +71.5% |
| Operating Income | -$2.1M | -10.6% | -4.5% |
| Net Income | -$2.4M | -14.4% | -12.9% |
| EPS (Basic) | -$0.85 | +46.2% | +62.6% |
| EPS (Diluted) | -$0.85 | +46.2% | +62.6% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.0M | -30.1% | -51.8% |
| Accounts Receivable | $4K | — | — |
| Inventory | $657K | +1.2% | +0.7% |
| Current Assets | $3.8M | -14.1% | -33.3% |
| Total Assets | $6.0M | -6.9% | -22.9% |
| Current Liabilities | $1.6M | -48.0% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$4.3M | -119.5% | — |
| Capital Expenditures | $13K | — | — |
| Investing Cash Flow | -$17K | -1937.3% | — |
| Financing Cash Flow | $5.2M | +41.4% | — |
| Free Cash Flow | -$4.3M | — | — |
| -52.6% |
| Total Liabilities | $1.8M | -45.0% | -51.8% |
| Stockholders' Equity | $4.2M | +33.2% | +4.1% |